Literature DB >> 17720506

Anti-ganglioside antibodies alter presynaptic release and calcium influx.

Brigitte Buchwald1, Gang Zhang, Angela K Vogt-Eisele, Weiyi Zhang, Raheleh Ahangari, John W Griffin, Hanns Hatt, Klaus V Toyka, Kazim A Sheikh.   

Abstract

Acute motor axonal neuropathy (AMAN) variant of Guillain-Barré syndrome is often associated with IgG anti-GM1 and -GD1a antibodies. The pathophysiological basis of antibody-mediated selective motor nerve dysfunction remains unclear. We investigated the effects of IgG anti-GM1 and -GD1a monoclonal antibodies (mAbs) on neuromuscular transmission and calcium influx in hemidiaphragm preparations and in cultured neurons, respectively, to elucidate mechanisms of Ab-mediated muscle weakness. Anti-GM1 and -GD1a mAbs depressed evoked quantal release to a significant yet different extent, without affecting postsynaptic currents. At equivalent concentrations, anti-GD1b, -GT1b, or sham mAbs did not affect neuromuscular transmission. At fourfold higher concentration, an anti-GD1b mAb (specificity described in immune sensory neuropathies) induced completely reversible blockade. In neuronal cultures, anti-GM1 and -GD1a mAbs significantly reduced depolarization-induced calcium influx. In conclusion, different anti-ganglioside mAbs induce distinct effects on presynaptic transmitter release by reducing calcium influx, suggesting that this is one mechanism of antibody-mediated muscle weakness in AMAN.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720506      PMCID: PMC2094038          DOI: 10.1016/j.nbd.2007.07.008

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  39 in total

1.  Genetic background influences P/Q-type Ca2+ channel alpha1A subunit mRNA expression in olfactory bulb and reproductive ability of N-type Ca2+ channel alpha1B subunit-deficient mice.

Authors:  Eiki Takahashil; Takeshi Nagasu
Journal:  Biochem Genet       Date:  2005-06       Impact factor: 1.890

2.  Anti-disialosyl antibodies mediate selective neuronal or Schwann cell injury at mouse neuromuscular junctions.

Authors:  Susan K Halstead; Ian Morrison; Graham M O'Hanlon; Peter D Humphreys; John A Goodfellow; Jaap J Plomp; Hugh J Willison
Journal:  Glia       Date:  2005-11-15       Impact factor: 7.452

3.  Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy.

Authors:  John A Goodfellow; Tyrone Bowes; Kazim Sheikh; Masaaki Odaka; Susan K Halstead; Peter D Humphreys; Eric R Wagner; Nobuhiro Yuki; Koichi Furukawa; Keiko Furukawa; Jaap J Plomp; Hugh J Willison
Journal:  J Neurosci       Date:  2005-02-16       Impact factor: 6.167

4.  High-affinity anti-ganglioside IgG antibodies raised in complex ganglioside knockout mice: reexamination of GD1a immunolocalization.

Authors:  M P Lunn; L A Johnson; S E Fromholt; S Itonori; J Huang; A A Vyas; J E Hildreth; J W Griffin; R L Schnaar; K A Sheikh
Journal:  J Neurochem       Date:  2000-07       Impact factor: 5.372

5.  Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside.

Authors:  N Yuki; M Yamada; M Koga; M Odaka; K Susuki; Y Tagawa; S Ueda; T Kasama; A Ohnishi; S Hayashi; H Takahashi; M Kamijo; K Hirata
Journal:  Ann Neurol       Date:  2001-06       Impact factor: 10.422

6.  Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome.

Authors:  B Buchwald; J Bufler; M Carpo; F Heidenreich; R Pitz; J Dudel; E Nobile-Orazio; K V Toyka
Journal:  Neurology       Date:  2001-01-09       Impact factor: 9.910

Review 7.  Pathogenesis of Guillain-Barré syndrome.

Authors:  R A Hughes; R D Hadden; N A Gregson; K J Smith
Journal:  J Neuroimmunol       Date:  1999-12       Impact factor: 3.478

8.  Guillain-Barré syndrome associated with IgG monospecific to ganglioside GD1b.

Authors:  T Miyazaki; S Kusunoki; K Kaida; M Shiina; I Kanazawa
Journal:  Neurology       Date:  2001-05-08       Impact factor: 9.910

Review 9.  Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes.

Authors:  N Yuki
Journal:  Lancet Infect Dis       Date:  2001-08       Impact factor: 25.071

10.  Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: a macro-patch-clamp study.

Authors:  B Buchwald; K V Toyka; J Zielasek; A Weishaupt; S Schweiger; J Dudel
Journal:  Ann Neurol       Date:  1998-12       Impact factor: 10.422

View more
  14 in total

1.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

2.  Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy.

Authors:  Simon N Fewou; Angie Rupp; Lauren E Nickolay; Kathryn Carrick; Kay N Greenshields; John Pediani; Jaap J Plomp; Hugh J Willison
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

3.  Effects of IgG anti-GM1 monoclonal antibodies on neuromuscular transmission and calcium channel binding in rat neuromuscular junctions.

Authors:  Sayako Hotta; Yoshihiko Nakatani; Toshie Kambe; Kenji Abe; Yutaka Masuda; Iku Utsumomiya; Kyoji Taguchi
Journal:  Exp Ther Med       Date:  2015-06-12       Impact factor: 2.447

4.  Neurophysiological and immunohistochemical studies of IgG anti-GM1 monoclonal antibody on neuromuscular transmission: effects in rat neuromuscular junctions.

Authors:  Sayako Hotta; Takumi Nagaoka; Kyoji Taguchi; Yoshihiko Nakatani; Iku Utsnomiya; Yutaka Masuda; Kenji Abe; Nobuhiro Yuki
Journal:  Neurol Sci       Date:  2013-07-03       Impact factor: 3.307

Review 5.  Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction.

Authors:  Jaap J Plomp; Hugh J Willison
Journal:  J Physiol       Date:  2009-06-29       Impact factor: 5.182

6.  An update on pathobiologic roles of anti-glycan antibodies in Guillain-Barré syndrome.

Authors:  Kazim A Sheikh; Gang Zhang
Journal:  F1000 Biol Rep       Date:  2010-03-25

7.  Cav2.1 voltage-dependent Ca2+ channel current is inhibited by serum from select patients with Guillain-Barré syndrome.

Authors:  Yoshihiko Nakatani; Sayako Hotta; Iku Utsunomiya; Keiko Tanaka; Keiko Hoshi; Toshi Ariga; Robert K Yu; Tadashi Miyatake; Kyoji Taguchi
Journal:  Neurochem Res       Date:  2008-05-14       Impact factor: 3.996

8.  The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice.

Authors:  Kay N Greenshields; Susan K Halstead; Femke M P Zitman; Simon Rinaldi; Kathryn M Brennan; Colin O'Leary; Luke H Chamberlain; Alistair Easton; Jennifer Roxburgh; John Pediani; Koichi Furukawa; Keiko Furukawa; Carl S Goodyear; Jaap J Plomp; Hugh J Willison
Journal:  J Clin Invest       Date:  2009-02-16       Impact factor: 14.808

9.  Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain-Barré syndrome.

Authors:  S Usuki; K Taguchi; S A Thompson; P B Chapman; R K Yu
Journal:  J Neurosci Res       Date:  2010-06       Impact factor: 4.164

Review 10.  Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review.

Authors:  Kenichi Kaida; Toshio Ariga; Robert K Yu
Journal:  Glycobiology       Date:  2009-02-24       Impact factor: 4.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.